Activating mutations in epidermal growth factor receptor (EGFR) are detected in up to 20% of lung adenocarcinomas1, and the standard treatment for these cancers is the use of EGFR tyrosine kinase inhibitors (TKIs). The gene discussed is EGFR; the disease is cancer.